» Articles » PMID: 37274833

Adaptability of High Dimensional Propensity Score Procedure in the Transition from ICD-9 to ICD-10 in the US Healthcare System

Overview
Journal Clin Epidemiol
Publisher Dove Medical Press
Specialty Public Health
Date 2023 Jun 5
PMID 37274833
Authors
Affiliations
Soon will be listed here.
Abstract

Background: High-Dimensional Propensity Score procedure (HDPS) is a data-driven approach to assist control for confounding in pharmacoepidemiologic research. The transition to the International Classification of Disease (ICD-9/10) in the US health system may pose uncertainty in applying the HDPS procedure.

Methods: We assembled a base cohort of patients in MarketScan Commercial Claims Database who had newly initiated celecoxib or traditional NSAIDs to compare gastrointestinal bleeding risk. We then created bootstrapped hypothetical cohorts from the base cohort with predefined patient selection patterns from the ICD eras. Three strategies for HDPS deployment were tested: 1) split the cohort by ICD era, deploy HDPS twice, and pool the relative risks (pooled RR), 2) consider codes from each ICD era as a separate data dimension and deploy HDPS in the entire cohort (data dimensions) and 3) map ICD codes from both eras to Clinical Classifications Software (CCS) concepts before deploying HDPS in the entire cohort (CCS mapping). We calculated percent bias and root-mean-squared error to compare the strategies.

Results: A similar bias reduction was observed in cohorts where patient selection pattern from each ICD era was comparable between the exposure groups. In the presence of considerable disparity in patient selection, we observed a bimodal distribution of propensity scores in the data dimensions strategy, indicating instrument-like covariates. Moreover, the CCS mapping strategy resulted in at least 30% less bias than pooled RR and data dimensions strategies (RMSE: 0.14, 0.19, 0.21, respectively) in this scenario.

Conclusion: Mapping ICD codes to a stable terminology like CCS serves as a helpful strategy to reduce residual bias when deploying HDPS in pharmacoepidemiologic studies spanning both ICD eras.

References
1.
Watson D, Harper S, Zhao P, Quan H, Bolognese J, Simon T . Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med. 2000; 160(19):2998-3003. DOI: 10.1001/archinte.160.19.2998. View

2.
Eisen G, Goldstein J, Hanna D, Rublee D . Meta-analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis. Aliment Pharmacol Ther. 2005; 21(5):591-8. DOI: 10.1111/j.1365-2036.2005.02383.x. View

3.
Brookhart M, Schneeweiss S, Rothman K, Glynn R, Avorn J, Sturmer T . Variable selection for propensity score models. Am J Epidemiol. 2006; 163(12):1149-56. PMC: 1513192. DOI: 10.1093/aje/kwj149. View

4.
Schneeweiss S . Automated data-adaptive analytics for electronic healthcare data to study causal treatment effects. Clin Epidemiol. 2018; 10:771-788. PMC: 6039060. DOI: 10.2147/CLEP.S166545. View

5.
Miao W, Geng Z, Tchetgen Tchetgen E . Identifying Causal Effects With Proxy Variables of an Unmeasured Confounder. Biometrika. 2020; 105(4):987-993. PMC: 7746017. DOI: 10.1093/biomet/asy038. View